β-amyloidosis and neurodegeneration in Alzheimer disease: Who's on first?

Neurology

Volumn 82, Issue 20, 2014, Pages 1756-1757

  Knopman, David S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; AMYLOIDOSIS; COGNITIVE DEFECT; EDITORIAL; HUMAN; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; ATROPHY; BRAIN; COGNITION; DEMENTIA; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT;

EID: 84902187152     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000438     Document Type: Editorial

References (15)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
2. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305: 275-283.
3. Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014;82: 1760-1767.
4. Ossenkoppele R, van der Flier WM, Verfaillie SCJ, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology 2014;82: 1768-1775.
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
6. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
7. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960-969.
8. Reiman EM, Caselli RJ, Chen K, et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98: 3334-3339.
9. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012;32:18227-18233.
10. Jack CR Jr, Wiste HJ, Knopman DS, et al. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology (in press 2014).
11. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain betaamyloid load approaches a plateau. Neurology 2013;80: 890-896.
12. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-367.
13. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009;360:2302-2309.
14. de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012;73:685-697.
15. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012;7:e31302.